Visual Acuity, Full-field Stimulus Thresholds, and Electroretinography for 4 Years in The Rate of Progression of USH2A-related Retinal Degeneration (RUSH2A) Study
Purpose: To describe progression of best-corrected visual acuity (BCVA), full-field stimulus thresholds (FST), and electroretinography (ERG) over 4 years in the USH2A-related Retinal Degeneration study and to assess their suitability as clinical trial endpoints. Design: Prospective natural history s...
Saved in:
| Main Authors: | David G. Birch, PhD, Peiyao Cheng, PhD, Maureen G. Maguire, PhD, Jacque L. Duncan, MD, Allison R. Ayala, MS, Janet K. Cheetham, PharmD, Nicole R. Doucet, MPH, Todd A. Durham, PhD, Abigail T. Fahim, MD, PhD, Frederick L. Ferris, III, MD, Rachel M. Huckfeldt, MD, PhD, Michele Melia, ScM, Michel Michaelides, MD (Res), Mark E. Pennesi, MD, PhD, José-Alain Sahel, MD, Katarina Stingl, MD, Ajoy Vincent, MBBS, MS, Christina Y. Weng, MD, MBA |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Ophthalmology Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666914524001842 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of effectiveness and safety of thrombolytic therapy to pulmonary emboli by endobronchial ultrasound-guided transbronchial needle injectionCentral MessagePerspective
by: Yuki Sata, MD, PhD, et al.
Published: (2023-12-01) -
Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies
by: Yusuke Inoue, MD, PhD, et al.
Published: (2025-08-01) -
Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L
by: Hideyuki Harada, MD, PhD, et al.
Published: (2025-06-01) -
Independent association of a 17q21 variant with exacerbations in type 2–low adult asthma
by: Yumi Ishiyama, MD, et al.
Published: (2025-08-01) -
A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer
by: Noriyuki Okonogi, MD, PhD, et al.
Published: (2025-03-01)